• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Geron Corp (GERN)

Common Shares
Sell: $1.76|Buy: $1.80|Change: 0.01 (-0.57%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products foroncology.

Address

149 Commonwealth Drive
Suite 2070
Menlo Park
CA
USA
94025

Telephone

+1 650 4737700

Website

https://www.geron.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Geron Corp Annual Report for 20262027-03-03T00:00:00
Geron Corp Fourth Quarter Earnings Conference Call for 20262027-02-25T08:00:00
Geron Corp Fourth Quarter Earnings Results for 20262027-02-25T00:00:00
Geron Corp Third Quarter Earnings Conference Call for 20262026-11-05T08:00:00
Geron Corp Third Quarter Earnings Results for 20262026-11-05T00:00:00
Geron Corp Second Quarter Earnings Conference Call for 20262026-08-06T08:00:00
Geron Corp Second Quarter Earnings Results for 20262026-08-06T00:00:00
Geron Corp Annual General Meeting for 20262026-05-21T14:00:00
Geron Corp First Quarter Earnings Conference Call for 20262026-05-07T08:00:00
Geron Corp First Quarter Earnings Results for 20262026-05-07T00:00:00
25th Annual Needham Virtual Healthcare Conference2026-04-13T11:00:00

Previous key dates

NameKey Date
25th Annual Needham Virtual Healthcare Conference2026-04-13T11:00:00
Barclays 28th Annual Global Healthcare Conference2026-03-10T10:30:00
Geron Corp Annual Report for 20252026-03-03T00:00:00
TD Cowen 46th Annual Healthcare Conference2026-03-02T13:10:00
Geron Corp Fourth Quarter Earnings Conference Call for 20252026-02-25T08:00:00
Geron Corp Fourth Quarter Earnings Results for 20252026-02-25T00:00:00
8th Annual Evercore Healthcare Conference2025-12-02T11:15:00
Stifel 2025 Healthcare Conference2025-11-11T11:40:00
Geron Corp Third Quarter Earnings Conference Call for 20252025-11-05T08:00:00
Geron Corp Third Quarter Earnings Results for 20252025-11-05T00:00:00
2025 Wells Fargo Healthcare Conference2025-09-04T12:45:00
Geron Corp Second Quarter Earnings Conference Call for 20252025-08-06T08:00:00
Geron Corp Second Quarter Earnings Results for 20252025-08-06T00:00:00
Geron Corp Annual General Meeting for 20252025-05-21T14:00:00
Geron Corp First Quarter Earnings Conference Call for 20252025-05-07T08:00:00
Geron Corp First Quarter Earnings Result for 20252025-05-07T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.